Recommendations for the safe use of high-risk medications in pediatrics

María José Otero , Belén Rodríguez Marrodan , Nuria Prieto Santos , Enrique Villalobos Pinto , Silvia Manrique Rodríguez , Rebeca Padilla Peinado , Cecilia M. Fernández-Llamazares , Aurora Madrid Rodríguez , representing the Spanish Association of Pediatrics, the Spanish Society of Hospital Pharmacy and Autonomous Communities
{"title":"Recommendations for the safe use of high-risk medications in pediatrics","authors":"María José Otero ,&nbsp;Belén Rodríguez Marrodan ,&nbsp;Nuria Prieto Santos ,&nbsp;Enrique Villalobos Pinto ,&nbsp;Silvia Manrique Rodríguez ,&nbsp;Rebeca Padilla Peinado ,&nbsp;Cecilia M. Fernández-Llamazares ,&nbsp;Aurora Madrid Rodríguez ,&nbsp;representing the Spanish Association of Pediatrics, the Spanish Society of Hospital Pharmacy and Autonomous Communities","doi":"10.1016/j.anpede.2025.503815","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The objectives of this consensus document were to establish a standardized list of high-risk medications for the pediatric population and to compile the recommended practices for their safe use with the aim of promoting the implementation of medication error prevention programs in health care centers.</div></div><div><h3>Method</h3><div>The Ministry of Health, the Spanish Institute for Safe Medication Practices, the Spanish Association of Pediatrics and the Spanish Society of Hospital Pharmacy and regional administration representatives participated in the project. The <em>Recommendations for the Safe Use of High-Risk Medications</em> was used as reference, and its contents adapted and expanded to address specific issues in the pediatric population based on the current evidence.</div></div><div><h3>Results</h3><div>The document provides a reference list of high-risk medicines in pediatric care. It recommends that health care centers, in addition to prioritizing interventions in relation to anticoagulants, insulins, opioids, neuromuscular blockers, IV potassium, oral methotrexate and cytostatic agents, also consider interventions for IV adrenergic agonists, aminoglycosides and vancomycin, drugs for moderate and minimal sedation, parenteral nutrition and IV paracetamol in pediatric patients. The document emphasizes the need to implement multiple safe practices at every stage of the medication use process, prioritizing those with the greatest effectiveness, and involving pediatricians, pharmacists and other healthcare professionals. It also highlights the importance of active involvement by patients and caregivers. Finally, it provides general guidelines common to all these medications, as well as specific practices for each prioritized pharmacological group or medication, which should be combined to enhance pediatric patient safety.</div></div><div><h3>Conclusion</h3><div>Developing programs to increase the safety of high-risk medications in pediatric patients is essential in order to reduce medication errors in this vulnerable population. The implementation of safe practices should be accompanied by continuous monitoring and periodic updates to guarantee effectiveness and strengthen the safety culture in health care centers.</div></div>","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"103 1","pages":"Article 503815"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales de pediatria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2341287925000596","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The objectives of this consensus document were to establish a standardized list of high-risk medications for the pediatric population and to compile the recommended practices for their safe use with the aim of promoting the implementation of medication error prevention programs in health care centers.

Method

The Ministry of Health, the Spanish Institute for Safe Medication Practices, the Spanish Association of Pediatrics and the Spanish Society of Hospital Pharmacy and regional administration representatives participated in the project. The Recommendations for the Safe Use of High-Risk Medications was used as reference, and its contents adapted and expanded to address specific issues in the pediatric population based on the current evidence.

Results

The document provides a reference list of high-risk medicines in pediatric care. It recommends that health care centers, in addition to prioritizing interventions in relation to anticoagulants, insulins, opioids, neuromuscular blockers, IV potassium, oral methotrexate and cytostatic agents, also consider interventions for IV adrenergic agonists, aminoglycosides and vancomycin, drugs for moderate and minimal sedation, parenteral nutrition and IV paracetamol in pediatric patients. The document emphasizes the need to implement multiple safe practices at every stage of the medication use process, prioritizing those with the greatest effectiveness, and involving pediatricians, pharmacists and other healthcare professionals. It also highlights the importance of active involvement by patients and caregivers. Finally, it provides general guidelines common to all these medications, as well as specific practices for each prioritized pharmacological group or medication, which should be combined to enhance pediatric patient safety.

Conclusion

Developing programs to increase the safety of high-risk medications in pediatric patients is essential in order to reduce medication errors in this vulnerable population. The implementation of safe practices should be accompanied by continuous monitoring and periodic updates to guarantee effectiveness and strengthen the safety culture in health care centers.
儿科高危药物安全使用建议
目的:本共识文件的目的是为儿科人群建立一个标准化的高危药物清单,并编制其安全使用的推荐做法,以促进卫生保健中心药物错误预防项目的实施。方法卫生部、西班牙安全用药实践研究所、西班牙儿科协会和西班牙医院药房协会以及区域管理代表参与了该项目。《高危药物安全使用建议》作为参考,并根据现有证据对其内容进行了调整和扩展,以解决儿科人群中的具体问题。结果提供了儿科高危用药参考清单。它建议卫生保健中心,除了优先考虑抗凝血剂、胰岛素、阿片类药物、神经肌肉阻滞剂、静脉钾、口服甲氨蝶呤和细胞抑制剂相关的干预措施外,还考虑对儿科患者的静脉肾上腺素能激动剂、氨基糖苷类和万古霉素、中度和轻度镇静药物、肠外营养和静脉扑热息痛进行干预。该文件强调需要在用药过程的每个阶段实施多种安全做法,优先考虑最有效的做法,并让儿科医生、药剂师和其他卫生保健专业人员参与。它还强调了患者和护理人员积极参与的重要性。最后,它提供了所有这些药物的通用指南,以及每个优先药理组或药物的具体实践,这些应该结合起来提高儿科患者的安全。结论为减少儿童高危人群的用药差错,必须制定相关方案,提高儿童高危药物的安全性。安全实践的实施应该伴随着持续的监测和定期的更新,以保证医疗保健中心的有效性和加强安全文化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信